How India Exports Atorvastatin to the World

In the United States, atorvastatin is approved through Abbreviated New Drug Applications (ANDAs), allowing generic versions to enter the market. The FDA's Orange Book lists multiple approved ANDAs for atorvastatin, indicating a competitive generic landscape. The FDA's import alert database does not currently list atorvastatin, suggesting no active import restrictions on this product. Given that 52.5% of India's atorvastatin exports are destined for the U.S., the absence of import alerts is favorable for Indian exporters.

In the European Union, atorvastatin is subject to marketing authorization by the European Medicines Agency (EMA). The EMA has conducted periodic safety update report single assessments (PSUSAs) for atorvastatin, with the most recent in October 2024, resulting in variations to the product information. These assessments ensure ongoing pharmacovigilance and compliance with EU Good Manufacturing Practice (GMP) requirements. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and monitoring of atorvastatin, aligning with similar standards.

Atorvastatin is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in global health. It is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different markets.

In India, atorvastatin is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for essential medicines; however, atorvastatin is not currently listed under price control, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceuticals, but atorvastatin is generally exempt from such requirements, facilitating smoother export processes.

The primary patents for atorvastatin have expired, leading to a robust generic market with multiple manufacturers producing the drug. This has resulted in increased competition and more affordable pricing globally.

In December 2025, the EMA completed a PSUSA for the combination of amlodipine and atorvastatin, leading to updates in product information to enhance patient safety. In January 2025, the FDA updated import alerts to reinforce that all unauthorized e-cigarettes may be detained without physical examination, reflecting the agency's commitment to regulating tobacco products. In August 2024, the EMA concluded a PSUSA for atorvastatin, resulting in variations to the product information to address new safety data. In June 2019, the EMA conducted a PSUSA for atorvastatin/ezetimibe, leading to updates in the product information to ensure continued safety and efficacy. In August 2018, the EMA completed a PSUSA for atorvastatin, resulting in harmonized prescribing information across the EU.

These developments highlight the dynamic regulatory environment surrounding atorvastatin, emphasizing the importance of continuous monitoring and compliance for stakeholders involved in its production and distribution.

Atorvastatin, a widely prescribed statin for lowering cholesterol, is primarily manufactured in India, which has established itself as a global hub for pharmaceutical production. However, the production of Atorvastatin's Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) imported from China. This dependency poses significant risks, as any disruption in the supply of these KSMs can directly impact the availability of the final product. For instance, in October 2025, the U.S. Pharmacopeia highlighted that 58% of KSMs used for U.S.-approved APIs are sourced from a single country, underscoring the vulnerability of the supply chain.

The COVID-19 pandemic further exposed these vulnerabilities, with lockdowns and export restrictions in China leading to supply chain disruptions. Although the situation has stabilized, the underlying risk remains due to the concentrated sourcing of critical raw materials. This reliance on a single country for essential KSMs necessitates strategic measures to diversify sourcing and enhance supply chain resilience.

TransData Nexus's proprietary trade data indicates that the top five Indian exporters of Atorvastatin account for 73.2% of total exports, with INTAS PHARMACEUTICALS LIMITED alone contributing 24.6%. This high supplier concentration amplifies the risk of supply disruptions, as issues affecting these key players can have a disproportionate impact on global availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, aiming to boost domestic manufacturing of critical APIs and reduce import dependence. As of December 2025, the scheme has led to the approval of 48 projects, resulting in the creation of manufacturing capacities for 26 KSMs and APIs, thereby reducing import dependency and enhancing supply chain resilience.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt maritime transport. Such disruptions can delay the delivery of essential raw materials and finished pharmaceutical products. Additionally, ongoing U.S.-China trade tensions have led to tariffs and export restrictions, further complicating the supply chain for APIs and KSMs.

Regulatory bodies like the U.S. Food and Drug Administration (FDA) have issued warnings to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP). In February 2025, the FDA highlighted quality control issues at facilities in both countries, emphasizing the need for stringent quality assurance measures to prevent supply chain disruptions.

• Diversify Sourcing of KSMs: Identify and develop alternative suppliers for critical KSMs to reduce dependency on a single country.

• Enhance Domestic Production: Leverage government incentives like the PLI Scheme to bolster domestic manufacturing capacities for APIs and KSMs.

• Strengthen Supplier Audits: Implement rigorous quality control and compliance audits for all suppliers to ensure adherence to cGMP standards.

• Develop Contingency Plans: Establish robust contingency strategies to address potential geopolitical and logistical disruptions in shipping routes.

• Monitor Regulatory Compliance: Stay informed about regulatory actions and compliance issues affecting key suppliers to proactively manage risks.

RISK_LEVEL: MEDIUM